How Handl Was 'Built To Buy' By UCB
The Inside Story On Gene Therapy Acquisition
Executive Summary
UCB has been looking to go deep into the gene therapy space for some time, CSO Dhaval Patel tells Scrip, saying that instead of treating symptoms, "you should be going for a cure."
You may also be interested in...
Y-mAbs Gives Thanks For First Approved Drug Danyelza
US regulators refused to accept the file for one of Y-mAbs's neuroblasoma drugs – omburtamab – in October but have given the green light to a second one, naxitamab.
Biogen Bets Big To Bag Sage Depression And Tremor Drugs
Rather than hitting the acquisition trial, Biogen has taken the licensing route to expand its psychiatric and neurological disorders pipeline.
Novartis Confident About Further Growth For 'Big Two'
As well as highlighting Novartis's burgeoning pipeline, the Swiss major's CEO is confident that its biggest earners will continue to growth for the next five years at least.
Existing Subscriber?
Sign in to continue reading.
Need a specific report? 1000+ reports available
Buy Reports
Need a specific report? 1000+ reports available
Buy Reports